

**We Claim:**

1. A method for the prevention or treatment of a cardiovascular, cardiopulmonary, or renal disease or condition in a human or mammal patient, the method comprising administering to the patient in need thereof an effective amount of:
  - (a) telmisartan or a polymorph or salt thereof; and
  - (b) simvastatin.
2. The method according to claim 1, wherein the disease or condition is hypertension combined with hyperlipidemia or atherosclerosis.
3. The method according to claim 1, wherein the disease or condition is asthma, bronchitis, or interstitial lung disease.
4. The method according to claim 1, wherein the disease or condition is type 2 diabetes mellitus.
5. The method according to claim 1, wherein the disease or condition is prediabetes.
6. The method according to claim 1, wherein the disease or condition is metabolic syndrome or insulin resistance in patients with normal blood pressure.
7. The method according to claim 1, wherein the disease or condition is hypertensive insulin resistance.
8. The method according to claim 1, wherein the patient is a human.
9. The method according to claim 8, wherein the patient has a fasting blood sugar level more than 110 mg of glucose per dL of plasma.

10. The method according to claim 8, wherein the patient has a blood level for triglyceride more than 150 mg/dL.

11. The method according to claim 10, wherein the patient is a female and has a blood level for HDL less than 40 mg/dL of plasma.

12. The method according to claim 10, wherein the patient is a male and has a blood level for HDL less than 50 mg/dL of plasma.

13. The method according to claim 6, wherein the patient has a systolic blood pressure greater than 130 mmHg and a diastolic blood pressure greater than 80 mmHg.

14. The method according to claim 11, wherein the simvastatin is administered in a daily dose of about 0.009 mg/kg body weight to 6.43 mg/kg body weight by oral route and the telmisartan or salt thereof is administered in a daily dose of about 0.143 mg/kg to 7.143 mg/kg body weight by oral route.

15. The method according to claim 12, wherein the simvastatin is administered in a daily dose of about 0.009 mg/kg body weight to 6.43 mg/kg body weight by oral route and the telmisartan or salt thereof is administered in a daily dose of about 0.143 mg/kg to 7.143 mg/kg body weight by oral route.

16. The method according to claim 11, wherein the simvastatin is administered in a daily dose of about 0.286 mg/kg body weight by parenteral route and the telmisartan or salt thereof is administered in a daily dose of about 0.286 mg/kg body weight by parenteral route.

17. The method according to claim 12, wherein the simvastatin is administered in a daily dose of about 0.286 mg/kg body weight by parenteral route and the telmisartan or salt thereof is administered in a daily dose of about 0.286 mg/kg body weight by parenteral route.

18. A pharmaceutical composition comprising:
  - (a) telmisartan or a polymorph or salt thereof; and
  - (b) simvastatin.
19. A pharmaceutical composition comprising:
  - (a) telmisartan or a polymorph or salt thereof;
  - (b) simvastatin; and
  - (c) a pharmaceutically acceptable excipient or carrier.
20. A pharmaceutical composition consisting essentially of:
  - (a) telmisartan or a polymorph or salt thereof;
  - (b) simvastatin; and
  - (c) a pharmaceutically acceptable excipient or carrier.
21. The pharmaceutical composition according to claim 18, wherein the pharmaceutical composition contains 20 mg to 200 mg of telmisartan and 2.5 mg to 40 mg of simvastatin.
22. The pharmaceutical composition according to claim 19, wherein the pharmaceutical composition contains 20 mg to 200 mg of telmisartan and 2.5 mg to 40 mg of simvastatin.
23. The pharmaceutical composition according to claim 20, wherein the pharmaceutical composition contains 20 mg to 200 mg of telmisartan and 2.5 mg to 40 mg of simvastatin.
24. The pharmaceutical composition according to claim 18, wherein the weight ratio of simvastatin to telmisartan or a polymorph or salt thereof is 1:2 to 1:16.
25. The pharmaceutical composition according to claim 19, wherein the weight ratio of simvastatin to telmisartan or a polymorph or salt thereof is 1:2 to 1:16.

26. The pharmaceutical composition according to claim 20, wherein the weight ratio of simvastatin to telmisartan or a polymorph or salt thereof is 1:2 to 1:16.
27. The pharmaceutical composition according to claim 18, further comprising a diuretic.
28. The pharmaceutical composition according to claim 19, further comprising a diuretic.
29. A pharmaceutical composition consisting essentially of:
  - (a) telmisartan or a polymorph or salt thereof;
  - (b) simvastatin;
  - (c) a diuretic; and
  - (d) a pharmaceutically acceptable excipient or carrier.
30. The pharmaceutical composition according to claim 27, wherein the diuretic is HCTZ or chlorthalidone.
31. The pharmaceutical composition according to claim 28, wherein the diuretic is HCTZ or chlorthalidone.
32. The pharmaceutical composition according to claim 29, wherein the diuretic is HCTZ or chlorthalidone.
33. The pharmaceutical composition according to claim 30, wherein the pharmaceutical composition contains 10 mg to 50 mg of HCTZ or chlorthalidone.
34. The pharmaceutical composition according to claim 31, wherein the pharmaceutical composition contains 10 mg to 50 mg of HCTZ or chlorthalidone.
35. The pharmaceutical composition according to claim 32, wherein the pharmaceutical composition contains 10 mg to 50 mg of HCTZ or chlorthalidone.